Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock: A Randomized Controlled Trial

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1) Cirrhotics with septic shock requiring norepinephrine dose >0.5ug/kg/min to maintain MAP > 65 mm Hg
•2) An informed consent from the patient or relative

•1.Patients with age less than 18 years or more than 65 years
•2.Severe known cardiopulmonary disease (Hypertension, structural or valvular heart disease, coronary artery disease, arrhythmias)
•4.Peripheral Vascular disease
•5.Gut Paralysis
•6.Intestinal obstruction
•7.Acute on chronic liver failure (ACLF )
•8.Cancer, hepato-cellular carcinoma (HCC), intrahepatic or extrahepatic malignancy
•9.Portal vein thrombosis
•10.Hepatic vein outflow tract obstruction (HVOTO )
•11.Pregnancy
•12.Patients with Pa02/FiO2 ratio <150
•13.Severe coagulopathy platelets <20,000 and INR > 4
•14.Active Bleed (Mucosal or variceal)
•15.Patients already on terlipressin in the last 48 hours
•16.Extremely moribund patients with an expected life expectancy of less than 24 hours
•17.Failure to give informed consent from family members.
•18.Patient enrolled in other clinical trials

发起方